| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| W M Wilson, R J Maugha. Evidence for a possible role of 5-hydroxytryptamine in the genesis of fatigue in man: administration of paroxetine, a 5-HT re-uptake inhibitor, reduces the capacity to perform prolonged exercise. Experimental physiology. vol 77. issue 6. 1993-02-26. PMID:1489548. |
seven healthy subjects exercised to exhaustion on a bicycle ergometer at a power output corresponding to 70% of maximum oxygen uptake after administration of either a placebo or 20 mg of paroxetine, a serotonin re-uptake inhibitor. |
1993-02-26 |
2023-08-11 |
human |
| J L Claghorn, A Kiev, K Rickels, W T Smith, G C Dunba. Paroxetine versus placebo: a double-blind comparison in depressed patients. The Journal of clinical psychiatry. vol 53. issue 12. 1993-02-23. PMID:1487471. |
paroxetine is a potent and selective serotonin reuptake inhibitor (ssri). |
1993-02-23 |
2023-08-11 |
Not clear |
| J L Katz, J W Griffiths, L G Sharpe, E B De Souza, J M Witki. Cocaine tolerance and cross-tolerance. The Journal of pharmacology and experimental therapeutics. vol 264. issue 1. 1993-02-23. PMID:8093724. |
tolerant rats showed no change in specific binding of [3h]sch 23390 to d1 receptors, [3h]spiperone to d2 receptors, [3h]gbr 12935 to dopamine uptake sites in striatum, [3h]paroxetine to serotonin uptake sites or [3h]mazindol to norepinephrine uptake sites in cortex or hippocampus. |
1993-02-23 |
2023-08-12 |
rat |
| M R Pranzatelli, J M Marten. Plasticity and ontogeny of the central 5-HT transporter: effect of neonatal 5,7-dihydroxytryptamine lesions in the rat. Brain research. Developmental brain research. vol 70. issue 2. 1993-02-09. PMID:1477953. |
to study the mechanism of this effect we measured the 5-ht transporter or uptake site, a presynaptic marker, using [3h]paroxetine binding. |
1993-02-09 |
2023-08-11 |
rat |
| S R Grimsley, M W Jan. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clinical pharmacy. vol 11. issue 11. 1993-01-21. PMID:1464219. |
paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. |
1993-01-21 |
2023-08-11 |
Not clear |
| S R Grimsley, M W Jan. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clinical pharmacy. vol 11. issue 11. 1993-01-21. PMID:1464219. |
the pharmacology and pharmacokinetics, adverse effects, drug interactions, efficacy, and dosage and administration of the new selective serotonin reuptake inhibitors paroxetine, sertraline, and fluvoxamine are reviewed. |
1993-01-21 |
2023-08-11 |
Not clear |
| H C Akunne, B R de Costa, A E Jacobson, K C Rice, R B Rothma. [3H] cocaine labels a binding site associated with the serotonin transporter in guinea pig brain: allosteric modulation by paroxetine. Neurochemical research. vol 17. issue 12. 1993-01-12. PMID:1461373. |
[3h] cocaine labels a binding site associated with the serotonin transporter in guinea pig brain: allosteric modulation by paroxetine. |
1993-01-12 |
2023-08-11 |
Not clear |
| H C Akunne, B R de Costa, A E Jacobson, K C Rice, R B Rothma. [3H] cocaine labels a binding site associated with the serotonin transporter in guinea pig brain: allosteric modulation by paroxetine. Neurochemical research. vol 17. issue 12. 1993-01-12. PMID:1461373. |
these studies suggest that, using membranes prepared from whole guinea pig brain, [3h]cocaine labels a binding site associated with serotonin transporter and that paroxetine and cocaine bind to different sites on the serotonin transporter. |
1993-01-12 |
2023-08-11 |
Not clear |
| C A Mathis, J M Gerdes, J D Enas, J M Whitney, S E Taylor, Y Zhang, D J McKenna, S Havlik, S J Peroutk. Binding potency of paroxetine analogues for the 5-hydroxytryptamine uptake complex. The Journal of pharmacy and pharmacology. vol 44. issue 10. 1993-01-04. PMID:1360504. |
binding potency of paroxetine analogues for the 5-hydroxytryptamine uptake complex. |
1993-01-04 |
2023-08-11 |
Not clear |
| C A Mathis, J M Gerdes, J D Enas, J M Whitney, S E Taylor, Y Zhang, D J McKenna, S Havlik, S J Peroutk. Binding potency of paroxetine analogues for the 5-hydroxytryptamine uptake complex. The Journal of pharmacy and pharmacology. vol 44. issue 10. 1993-01-04. PMID:1360504. |
the in-vitro inhibition constants (ki) of 14 structural analogues of the potent 5-hydroxytryptamine (5-ht)-uptake inhibitor paroxetine were determined to assess the structure-affinity relationship of these derivatives. |
1993-01-04 |
2023-08-11 |
Not clear |
| C A Mathis, J M Gerdes, J D Enas, J M Whitney, S E Taylor, Y Zhang, D J McKenna, S Havlik, S J Peroutk. Binding potency of paroxetine analogues for the 5-hydroxytryptamine uptake complex. The Journal of pharmacy and pharmacology. vol 44. issue 10. 1993-01-04. PMID:1360504. |
a goal of these studies was to determine those positions on paroxetine which could be derivatized without significantly decreasing the affinity of the drug for the binding site, so that radiolabels such as [18f]fluoroalkyl groups might be appended for future in-vivo imaging studies of the 5-ht uptake system. |
1993-01-04 |
2023-08-11 |
Not clear |
| C A Mathis, J M Gerdes, J D Enas, J M Whitney, S E Taylor, Y Zhang, D J McKenna, S Havlik, S J Peroutk. Binding potency of paroxetine analogues for the 5-hydroxytryptamine uptake complex. The Journal of pharmacy and pharmacology. vol 44. issue 10. 1993-01-04. PMID:1360504. |
using the methyl moiety as a steric probe for these studies, it was found that the rank order of potency of various methyl-substituted paroxetine analogues for inhibiting the binding of [3h]paroxetine to the 5-ht re-uptake site was: 4'-approximately equal to 3'-approximately equal to 2''- > 2'-approximately equal to 1- > 5''- > 6''-methyl. |
1993-01-04 |
2023-08-11 |
Not clear |
| P Bauman. Clinical pharmacokinetics of citalopram and other selective serotonergic reuptake inhibitors (SSRI). International clinical psychopharmacology. vol 6 Suppl 5. 1992-12-23. PMID:1431018. |
within the last years, several new and more selective serotonin uptake inhibitors have been introduced in clinical practice, including trazodone, citalopram, paroxetine, femoxetine, fluvoxamine and fluoxetine. |
1992-12-23 |
2023-08-11 |
Not clear |
| W F Boye. Potential indications for the selective serotonin reuptake inhibitors. International clinical psychopharmacology. vol 6 Suppl 5. 1992-12-23. PMID:1431022. |
the selective serotonin reuptake inhibitors (ssris) include fluoxetine, fluvoxamine, citalopram, paroxetine and sertraline. |
1992-12-23 |
2023-08-11 |
Not clear |
| A M Johnso. Paroxetine: a pharmacological review. International clinical psychopharmacology. vol 6 Suppl 4. 1992-12-16. PMID:1331230. |
paroxetine has been characterized as a highly potent and selective 5-hydroxytryptamine (serotonin) reuptake inhibitor. |
1992-12-16 |
2023-08-11 |
Not clear |
| A M Johnso. Paroxetine: a pharmacological review. International clinical psychopharmacology. vol 6 Suppl 4. 1992-12-16. PMID:1331230. |
this profile supports the evidence from clinical studies that paroxetine is an effective and well-tolerated antidepressant with substantial advantages over the tricyclic antidepressants and other selective serotonin reuptake inhibitors. |
1992-12-16 |
2023-08-11 |
Not clear |
| D G Grahame-Smit. Serotonin in affective disorders. International clinical psychopharmacology. vol 6 Suppl 4. 1992-12-16. PMID:1431011. |
inhibition of reuptake by drugs selective for 5-ht, such as paroxetine, has important acute and chronic effects on 5-ht systems and function, and upon other neurotransmitter systems with which 5-ht interacts. |
1992-12-16 |
2023-08-11 |
Not clear |
| P N Jenne. Paroxetine: an overview of dosage, tolerability, and safety. International clinical psychopharmacology. vol 6 Suppl 4. 1992-12-16. PMID:1431015. |
paroxetine is a new selective serotonin reuptake inhibitor which has been extensively evaluated as an antidepressant in clinical trials and a large computerized safety database has been accumulated. |
1992-12-16 |
2023-08-11 |
Not clear |
| S A Montgomer. The advantages of paroxetine in different subgroups of depression. International clinical psychopharmacology. vol 6 Suppl 4. 1992-12-16. PMID:1431017. |
paroxetine is a selective serotonin reuptake inhibitor that is now licensed in various countries in europe. |
1992-12-16 |
2023-08-11 |
Not clear |
| S C Risch, C B Nemerof. Neurochemical alterations of serotonergic neuronal systems in depression. The Journal of clinical psychiatry. vol 53 Suppl. 1992-12-11. PMID:1331029. |
specifically, studies have revealed (1) decreases in brain concentrations of serotonin and decreases in cerebrospinal fluid (csf) concentrations of 5-hydroxyindoleacetic acid (5-hiaa) in a sizeable subgroup of depressed patients; (2) alterations in both presynaptic and postsynaptic cns serotonergic receptors in depressed patients; (3) alterations in putative peripheral markers of cns serotonergic function such as platelet serotonin uptake, platelet [3h]imipramine or [3h]paroxetine binding, platelet 5-ht2 receptor density, and whole blood serotonin content in depressed patients; (4) that virtually all known antidepressant agents, regardless of their receptor-specific properties, have been shown to increase the efficacy of cns serotonergic neurotransmission; (5) that in patients treated with antidepressants who exhibit a remission, rapid depletion of serotonin results in a prompt clinical relapse; and (6) that all known serotonin re-uptake blockers thus far studied have been demonstrated to be clinically effective antidepressant medications. |
1992-12-11 |
2023-08-11 |
Not clear |